-+ 0.00%
-+ 0.00%
-+ 0.00%

Erasca to discuss preliminary Phase 1 ERAS-0015 dose-escalation data in RAS-mutant tumors

PUBT·04/27/2026 12:35:38
Listen to the news
Erasca to discuss preliminary Phase 1 ERAS-0015 dose-escalation data in RAS-mutant tumors
  • Erasca scheduled a conference call and webcast for 4:30 p.m. ET to discuss preliminary Phase 1 dose-escalation results for pan-RAS molecular glue ERAS-0015 in patients with RAS-mutant solid tumors.
  • Data have not yet been presented; management plans to review early signals from ongoing dose escalation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Erasca Inc. published the original content used to generate this news brief on April 27, 2026, and is solely responsible for the information contained therein.